Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured from a Genetically Engineered Strain of Measles Virus in Patients with Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor
Sponsor: Mayo Clinic
Listed as NCT02700230, this PHASE1 trial focuses on Metastatic Malignant Peripheral Nerve Sheath Tumor and Neurofibromatosis Type 1 and remains completed. Sponsored by Mayo Clinic, it has been updated 18 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
18 versions recorded-
Oct 2024 — Present [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1
▶ Show 13 earlier versions
-
Aug 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Apr 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Apr 2023 [monthly]
Recruiting PHASE1
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
May 2019 — Jun 2020 [monthly]
Recruiting PHASE1
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Oct 2017 — Mar 2018 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jun 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .